NR3C1 and acute lymphoblastic leukemia: Using this data, we have chosen five pre-B-ALL (Fig. 3) and five T-ALL (Fig. 4) cell lines, based on their moderate levels of GCR expression and intermediate sensitivity to Dexa, and performed combination treatments using Dexa and either lysosomal (HCQ, Lys-05) or autophagy inhibitors (SAR405, PIK-III) (for ZIP scores, see Table 2 and Supplementary Fig. 3d).